Compare SHAZ & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHAZ | MLYS |
|---|---|---|
| Founded | 2024 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | 2025 | 2023 |
| Metric | SHAZ | MLYS |
|---|---|---|
| Price | $49.96 | $23.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $110.00 | $48.50 |
| AVG Volume (30 Days) | 1.2M | ★ 1.2M |
| Earning Date | 11-15-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,566,631.00 | N/A |
| Revenue This Year | $7,470.09 | N/A |
| Revenue Next Year | $1,195.12 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 257.44 | N/A |
| 52 Week Low | $16.55 | $22.30 |
| 52 Week High | $97.48 | $47.65 |
| Indicator | SHAZ | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 44.25 | 41.01 |
| Support Level | $48.65 | $22.36 |
| Resistance Level | $62.37 | $31.19 |
| Average True Range (ATR) | 3.68 | 1.37 |
| MACD | -0.13 | -0.43 |
| Stochastic Oscillator | 27.65 | 15.65 |
SharonAI Holdings Inc is a neocloud operator, purpose-built to power the next generation of artificial intelligence (AI) and high-performance computing (HPC). The Company's infrastructure is architected from the ground up to meet the specific, intensive, and complex demands of modern AI training and inference workloads, machine learning, and Generative AI. Its services include: Sovereign AI Australia, GPU-as-a-Service, SHARON AI Cloud, SHARON AI Private Cloud, Virtual Private Clusters, HPC Servers, and SHARON AI Studio. The company's products are: SHARON AI Supercluster, GPU Fleet, Virtual Servers, Cloud Storage, and Machine Learning & Infrastructure. The Company operates in one operating segment, High Performance Compute Services (HPC).
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.